Jasper Therapeutics (NASDAQ:JSPR) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Jasper Therapeutics (NASDAQ:JSPR) from a hold rating to a sell rating in a report released on Saturday morning.

Other equities analysts also recently issued research reports about the company. Piper Sandler began coverage on Jasper Therapeutics in a research report on Wednesday. They issued an “overweight” rating and a $2.00 price objective for the company. Royal Bank Of Canada set a $3.00 target price on Jasper Therapeutics and gave the stock a “sector perform” rating in a report on Friday, May 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Finally, TD Cowen lowered Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Jasper Therapeutics currently has an average rating of “Hold” and a consensus price target of $8.17.

Jasper Therapeutics Trading Down 8.5%

NASDAQ:JSPR opened at $0.79 on Friday. Jasper Therapeutics has a 1 year low of $0.32 and a 1 year high of $3.14. The firm has a 50 day moving average of $0.59 and a 200-day moving average of $0.91. The stock has a market capitalization of $22.12 million, a P/E ratio of -0.50 and a beta of 3.02.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. As a group, analysts forecast that Jasper Therapeutics will post -1.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of JSPR. Goldman Sachs Group Inc. lifted its holdings in Jasper Therapeutics by 6,394.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock worth $3,196,000 after buying an additional 1,719,602 shares in the last quarter. Acorn Capital Advisors LLC bought a new position in Jasper Therapeutics in the 3rd quarter valued at $3,291,000. Velan Capital Investment Management LP increased its stake in shares of Jasper Therapeutics by 86.1% in the 3rd quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock valued at $6,206,000 after buying an additional 1,234,567 shares during the period. Woodline Partners LP acquired a new stake in shares of Jasper Therapeutics in the 3rd quarter valued at $2,475,000. Finally, Millennium Management LLC raised its position in shares of Jasper Therapeutics by 194.2% during the fourth quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock worth $1,965,000 after acquiring an additional 708,844 shares during the last quarter. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.